Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
There's a post on the Rule Breakers Biotechnology board about a company (Valentis - NASDAQ: VLTS) that has a drug to treat PAD that just completed Phase IIb trial with favorable results. You can find the story on Yahoo! Finance, if you're not an RB subscriber.

This may be a significant threat to watch, both for FOXH and Spectranetics.

Bob (still long FOXH)
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.